Duffau Hugues
Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Medical Center, 80 Avenue Augustin Fliche, 34295, Montpellier, France.
National Institute for Health and Medical Research (INSERM), U1051 Laboratory, Team "Brain Plasticity, Stem Cells and Glial Tumors", Institute for Neurosciences of Montpellier, Montpellier University Medical Center, 34091, Montpellier, France.
Acta Neurochir (Wien). 2016 Jan;158(1):51-8. doi: 10.1007/s00701-015-2621-3. Epub 2015 Nov 3.
Total or subtotal surgical resection of WHO grade II glioma (diffuse low-grade glioma, DLGG) can significantly increase survival. Moreover, a supratotal resection, i.e., an extended resection with a margin beyond MR imaging abnormalities, could decrease the risk of malignant transformation. Here, the goal is to analyze the long-term functional and oncological outcomes following supratotal resection for DLGG.
Sixteen consecutive patients who underwent supratotal resection for a DLGG with a minimum follow-up of 8 years after surgery were included. The resection was continued up to functional cortical and subcortical structures defined by intrasurgical electrical mapping. The extent of resection was evaluated on postoperative FLAIR-weighted MR imaging. Data regarding clinicoradiological features, therapeutic management, and outcomes were analyzed.
Seven men and nine women (mean age, 41.3 years, range, 26-63 years) were included (seizure in 15 cases, one incidental discovery). All patients resumed a normal life after surgery (no neurological deficits, no epilepsy). The volume of postoperative cavity was larger than the preoperative tumor volume in the 16 patients. Neuropathological examination confirmed the diagnosis of WHO grade II glioma in all cases. No adjuvant treatment was administrated after resection. The mean duration of postoperative follow-up was 132 months (range, 97-198 months). There was no relapse in eight cases. Eight patients experienced tumor recurrence, with an average time to relapse of 70.3 months (range, 32-105 months), but without malignant transformation. Five of them have been re-treated, with a reoperation (two cases), chemotherapy (three cases) and radiotherapy (two cases). All patients continue to enjoy a normal life.
This is the first series demonstrating the prolonged impact of supratotal resection on malignant transformation of DLGG. These original data may suggest to remove a margin around the FLAIR-weighted MR imaging abnormalities in a more systematic manner for DLGG not involving eloquent structures.
世界卫生组织(WHO)二级胶质瘤(弥漫性低级别胶质瘤,DLGG)的全切除或次全切除可显著提高生存率。此外,超全切除,即切除范围超出磁共振成像(MR)异常边界的扩大切除,可降低恶性转化风险。在此,目的是分析DLGG超全切除后的长期功能和肿瘤学结局。
纳入16例因DLGG接受超全切除且术后至少随访8年的连续患者。切除持续至术中电生理图谱确定的功能皮质和皮质下结构。术后在液体衰减反转恢复(FLAIR)加权MR成像上评估切除范围。分析临床放射学特征、治疗管理及结局相关数据。
纳入7例男性和9例女性(平均年龄41.3岁,范围26 - 63岁)(15例有癫痫发作,1例为偶然发现)。所有患者术后恢复正常生活(无神经功能缺损,无癫痫)。16例患者术后腔隙体积大于术前肿瘤体积。神经病理学检查在所有病例中均确诊为WHO二级胶质瘤。切除后未给予辅助治疗。术后平均随访时间为132个月(范围97 - 198个月)。8例无复发。8例患者出现肿瘤复发,平均复发时间为70.3个月(范围32 - 105个月),但无恶性转化。其中5例接受了再次治疗,包括再次手术(2例)、化疗(3例)和放疗(2例)。所有患者继续正常生活。
这是首个证明超全切除对DLGG恶性转化有长期影响的系列研究。这些原始数据可能提示,对于不涉及明确功能结构的DLGG,更系统地切除FLAIR加权MR成像异常周围的边界。